Story Highlights
- A DOJ investigation found that Black and Hispanic applicants to Yale School of Medicine had a substantially higher chance of admission than white or Asian applicants with stronger grade-point averages and test scores.
- Yale’s own 2023 amicus brief — in which the school said it could not maintain diversity without explicit race consideration — was cited as evidence of discriminatory intent.
- The Justice Department sent a formal letter to Yale seeking a voluntary resolution agreement, while preserving the right to pursue litigation if compliance is not achieved.
What Happened
Harmeet Dhillon, assistant attorney general for civil rights at the Department of Justice, sent a formal letter to Yale University on Thursday concluding that the Yale School of Medicine had illegally continued to consider race in its admissions process in direct violation of the Supreme Court’s 2023 ruling in Students for Fair Admissions. The investigation, described as spanning roughly one year, reviewed application data, institutional policies, and internal records that the DOJ concluded amounted to a deliberate effort to circumvent the court’s clear prohibition on race-conscious admissions.
The DOJ’s letter stated that Black and Hispanic applicants to the medical school were admitted at materially higher rates than white and Asian applicants despite the latter groups presenting stronger academic profiles on average, including higher grade-point averages and medical school entrance examination scores. Dhillon described Yale’s conduct as “a willful failure to comply” with the Supreme Court’s decision, pointing in particular to a lack of any measurable change in Yale’s admissions outcomes in the years since the ruling took effect.
Particularly striking in the DOJ’s legal argument was its use of Yale’s own prior public statements against the university. In a 2023 amicus brief filed in the Students for Fair Admissions case, Yale had told the Supreme Court that it would be unable to maintain diverse medical school classes without explicitly considering applicants’ race. The DOJ noted that Yale’s admissions outcomes remained largely unchanged after the ruling, and argued that this continuity — precisely what Yale had claimed would be impossible under race-neutral policies — constituted direct evidence that race discrimination had continued.
The Trump administration’s action against Yale follows a notice sent to the University of California, Los Angeles, the previous week. In that case, the DOJ joined an existing lawsuit initially filed by Do No Harm, a group that advocates against diversity initiatives in medicine, alleging that UCLA’s medical school had similarly continued to discriminate against applicants based on race after the Supreme Court ruling. Yale is the second medical school targeted by the DOJ in the span of eight days, signaling a structured and deliberate enforcement campaign rather than isolated legal actions.
Yale officials and the attorney named in the DOJ letter did not immediately respond to requests for comment following the announcement. The Justice Department indicated it is seeking to enter a voluntary resolution agreement with the university, an approach that would allow Yale to avoid litigation if it agrees to adopt admissions practices fully compliant with federal anti-discrimination law. If voluntary compliance cannot be secured, the agency has reserved authority to pursue enforcement through the courts under Title VI of the Civil Rights Act of 1964.
Why It Matters
The DOJ’s action against Yale raises fundamental questions about how American medical schools can simultaneously honor the Supreme Court’s prohibition on race-conscious admissions while pursuing student body diversity that the medical profession argues is clinically and socially essential. The tension the administration is exploiting is real: medical schools have long argued that a diverse physician workforce improves patient outcomes, particularly in underserved communities, and that abandoning race as a consideration will produce less diverse graduating classes with real public health consequences.
For the Trump administration, the broader enforcement campaign against elite universities serves a dual purpose. It fulfills a core political commitment to dismantling what the president and his allies characterize as ideological discrimination against white and Asian applicants. Simultaneously, it applies sustained institutional pressure to universities that have been among the most vocal critics of the administration’s domestic policies, from immigration to research funding.
The Yale action also highlights a structural bind that medical schools now face. Administration officials have applied what legal analysts describe as a “disparate impact” framework in reverse — arguing that even if an admissions policy is facially race-neutral, its outcomes can still constitute discrimination if they systematically favor one racial group over others. This creates a situation in which schools that proactively diversify their classes, whether through explicit racial consideration or through aggressive outreach to underrepresented communities, risk facing federal allegations regardless of the mechanism they employ.
For prospective medical students and applicants, the enforcement campaign introduces new uncertainty into a process that was already significantly altered by the 2023 Supreme Court decision. Medical school applicants cannot fully anticipate what a school’s admissions process looks like during an active federal investigation, and institutions under scrutiny may adjust their practices abruptly, creating inconsistency from one application cycle to the next.
Economic and Global Context
The medical education sector in the United States encompasses more than 150 accredited schools and collectively trains the physicians who staff a healthcare system representing approximately 18 percent of the national economy. Federal research funding — distributed through entities like the National Institutes of Health — flows heavily to institutions including Yale, which received hundreds of millions of dollars in federal grants for medical research in recent years. The possibility that federal funding could be conditioned on compliance with the administration’s admissions standards is a significant financial lever.
Beyond Yale and UCLA, the DOJ has in recent months sought admissions data from medical schools across the country, reviewing test scores, racial demographics, ZIP codes, and alumni connections. This data-gathering operation signals that further enforcement actions against other institutions may be forthcoming. The administration’s first-day executive order targeting diversity, equity, and inclusion programs at federally funded institutions has already resulted in terminated grants for research tied to health disparities and workforce diversification.
Internationally, American medical schools compete for top students globally, and the reputational and regulatory environment they operate in affects their ability to attract talent and research investment. Prolonged legal uncertainty about admissions practices may complicate recruitment, particularly from countries where diverse medical training programs are considered a positive institutional attribute.
Implications
For Yale, the immediate priority will be determining whether a voluntary resolution agreement is achievable and on what terms the administration would accept compliance. The university’s legal team must assess whether its current admissions process can be defended under the DOJ’s framework, or whether substantial reforms are required to avoid prolonged and costly litigation.
For the medical education community broadly, the paired actions against Yale and UCLA signal that no institution’s reputation or size provides protection from scrutiny. Accrediting bodies and medical school associations will face pressure to issue guidance to members on how to conduct admissions in a manner that satisfies both federal anti-discrimination law and the profession’s longstanding diversity goals.
For the Trump administration, a successful voluntary resolution with Yale would allow the DOJ to claim a landmark compliance victory at one of the country’s most prestigious institutions — a politically valuable outcome heading into the 2026 midterm election cycle. For civil rights advocates, the enforcement campaign represents what they characterize as a systematic assault on gains that have taken decades to achieve in a profession historically dominated by white male practitioners.
